Cancer immunotherapy .net
Information on human tumours 4
tumour type
Data in brief:

Intralesional interleukin-2 in metastatic malignant melanoma.

Intralesional IL-2 in metastases results in complete remissions in 2 patients.

85% of metastases have complete remission after intratumoral IL-2

Imiquimod plus IL-2 increases response rate compared to imiquimod as single therapeuticum in fase I/II study.
Green et al. (2007) Br.J.Dermatol. 156, 337-45
Phoehler et al. (2004) Hautartz 55, 171-5
Br.J.Cancer 2003; 89, 1620-6
tumour type
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitve to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors

Information for patients

I want to support this research or  more information on the EPTI fund supporting this research
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands